Decreased polycystin 2 expression alters calcium-contraction coupling and changes β-adrenergic signaling pathways
- PMID: 25368166
- PMCID: PMC4246301
- DOI: 10.1073/pnas.1415933111
Decreased polycystin 2 expression alters calcium-contraction coupling and changes β-adrenergic signaling pathways
Abstract
Cardiac disorders are the main cause of mortality in autosomal-dominant polycystic kidney disease (ADPKD). However, how mutated polycystins predispose patients with ADPKD to cardiac pathologies before development of renal dysfunction is unknown. We investigate the effect of decreased levels of polycystin 2 (PC2), a calcium channel that interacts with the ryanodine receptor, on myocardial function. We hypothesize that heterozygous PC2 mice (Pkd2(+/-)) undergo cardiac remodeling as a result of changes in calcium handling, separate from renal complications. We found that Pkd2(+/-) cardiomyocytes have altered calcium handling, independent of desensitized calcium-contraction coupling. Paradoxically, in Pkd2(+/-) mice, protein kinase A (PKA) phosphorylation of phospholamban (PLB) was decreased, whereas PKA phosphorylation of troponin I was increased, explaining the decoupling between calcium signaling and contractility. In silico modeling supported this relationship. Echocardiography measurements showed that Pkd2(+/-) mice have increased left ventricular ejection fraction after stimulation with isoproterenol (ISO), a β-adrenergic receptor (βAR) agonist. Blockers of βAR-1 and βAR-2 inhibited the ISO response in Pkd2(+/-) mice, suggesting that the dephosphorylated state of PLB is primarily by βAR-2 signaling. Importantly, the Pkd2(+/-) mice were normotensive and had no evidence of renal cysts. Our results showed that decreased PC2 levels shifted the βAR pathway balance and changed expression of calcium handling proteins, which resulted in altered cardiac contractility. We propose that PC2 levels in the heart may directly contribute to cardiac remodeling in patients with ADPKD in the absence of renal dysfunction.
Keywords: calcium signaling; excitation contraction coupling; β-adrenergic receptor blocker.
Conflict of interest statement
The authors declare no conflict of interest.
Figures






Similar articles
-
Deletion of cardiac polycystin 2/PC2 results in increased SR calcium release and blunted adrenergic reserve.Am J Physiol Heart Circ Physiol. 2020 Nov 1;319(5):H1021-H1035. doi: 10.1152/ajpheart.00302.2020. Epub 2020 Sep 18. Am J Physiol Heart Circ Physiol. 2020. PMID: 32946258 Free PMC article.
-
Polycystin 2-dependent cardio-protective mechanisms revealed by cardiac stress.Pflugers Arch. 2017 Nov;469(11):1507-1517. doi: 10.1007/s00424-017-2042-7. Epub 2017 Jul 31. Pflugers Arch. 2017. PMID: 28762163 Free PMC article.
-
Decreased Polycystin 2 Levels Result in Non-Renal Cardiac Dysfunction with Aging.PLoS One. 2016 Apr 15;11(4):e0153632. doi: 10.1371/journal.pone.0153632. eCollection 2016. PLoS One. 2016. PMID: 27081851 Free PMC article.
-
Recent advances in cardiac beta(2)-adrenergic signal transduction.Circ Res. 1999 Nov 26;85(11):1092-100. doi: 10.1161/01.res.85.11.1092. Circ Res. 1999. PMID: 10571541 Review.
-
Polycystin 2: A calcium channel, channel partner, and regulator of calcium homeostasis in ADPKD.Cell Signal. 2020 Feb;66:109490. doi: 10.1016/j.cellsig.2019.109490. Epub 2019 Dec 2. Cell Signal. 2020. PMID: 31805375 Free PMC article. Review.
Cited by
-
Arrhythmogenesis in the aged heart following ischaemia-reperfusion: role of transient receptor potential vanilloid 4.Cardiovasc Res. 2022 Mar 16;118(4):1126-1137. doi: 10.1093/cvr/cvab141. Cardiovasc Res. 2022. PMID: 33881517 Free PMC article.
-
C33(S), a novel PDE9A inhibitor, protects against rat cardiac hypertrophy through upregulating cGMP signaling.Acta Pharmacol Sin. 2017 Sep;38(9):1257-1268. doi: 10.1038/aps.2017.38. Epub 2017 Jun 26. Acta Pharmacol Sin. 2017. PMID: 28649129 Free PMC article.
-
PKD2: An Important Membrane Protein in Organ Development.Cells. 2024 Oct 17;13(20):1722. doi: 10.3390/cells13201722. Cells. 2024. PMID: 39451240 Free PMC article. Review.
-
Heterotrimeric G protein signaling in polycystic kidney disease.Physiol Genomics. 2016 Jul 1;48(7):429-45. doi: 10.1152/physiolgenomics.00027.2016. Epub 2016 May 13. Physiol Genomics. 2016. PMID: 27199453 Free PMC article. Review.
-
Generation and phenotypic characterization of Pde1a mutant mice.PLoS One. 2017 Jul 27;12(7):e0181087. doi: 10.1371/journal.pone.0181087. eCollection 2017. PLoS One. 2017. PMID: 28750036 Free PMC article.
References
-
- Schrier RW. Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2009;20(9):1888–1893. - PubMed
-
- Bardají A, et al. Cardiac involvement in autosomal-dominant polycystic kidney disease: a hypertensive heart disease. Clin Nephrol. 2001;56(3):211–220. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous